• CAY10499 and the ACLY–TAM Evidence Boundary

  2026-10-13

  CAY10499 is described by APExBIO as a multi-target lipase inhibitor with reported activity against human HSL, MGL, and FAAH in biochemical assays. A separate 2026 Advanced Science study implicates extracellular-vesicle-transferred ACLY in immunosuppressive macrophage differentiation and hepatocellular carcinoma progression. The supplied evidence does not show that CAY10499 was used in, or directly tests the ACLY mechanism described in, that study.

• ER-Targeted Peptide Assembly in Cancer Cells

  2026-10-13

  A 2025 Biomacromolecules study reports that alkaline-phosphatase-responsive, ER-targeting peptide assemblies selectively stressed cancer-cell endoplasmic reticulum and reduced the concentration threshold for cell killing. The findings support a model of organelle-directed cancer-cell modulation, but the supplied evidence does not establish clinical efficacy, broad cancer selectivity, or a role for caspase-4 or pyroptosis.

• SEMA3E, Beige Adipocytes and β-Catenin Signaling

  2026-10-12

  A source-grounded overview of a mouse study linking SEMA3E to beige adipocyte differentiation and thermogenesis through β-catenin signaling, with emphasis on evidence strength and translational limits.

• SARS-CoV-2 Nucleocapsid Condensation and GCG

  2026-10-12

  Zhao et al. investigated whether RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein contributes to viral biology and whether it can be disrupted chemically. The study linked nucleocapsid condensation to viral replication-related phenotypes and reported inhibition by the green-tea polyphenol GCG, while leaving important questions about specificity, variant generalizability, and clinical relevance unresolved.

• EZ Cap™ Human PTEN mRNA: Evidence and Limits

  2026-10-10

  A source-grounded overview of PTEN mRNA design, nanoparticle-delivery evidence, interpretation boundaries, and key limitations for cancer research and gene therapy research.

• Lactobacillus, UDCA, and Immune Control in Colitis

  2026-10-09

  Deng et al. connect Lactobacillus acidophilus with the microbiota-derived metabolite ursodeoxycholic acid to explain how probiotic treatment may rebalance ulcerative colitis immunity. Their mouse and cell-based evidence links UDCA with enhanced Treg differentiation, reduced M1 macrophage polarization, and regulation of the RapGap/PI3K-AKT/NF-κB axis, while also leaving important questions about causality and clinical translation.

• Extracellular Vesicles, ACLY, and HCC Macrophages

  2026-10-09

  A 2026 Advanced Science study identifies extracellular vesicle-transferred ATP-citrate lyase (ACLY) as a metabolic signal that promotes monocyte differentiation into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. The work connects ACLY-dependent palmitate production and protein S-palmitoylation with tumor progression and proposes targeted vesicle delivery as a way to improve checkpoint immunotherapy in preclinical models.

• PSI-7977 and BAP1: Evidence Boundaries

  2026-10-08

  PSI-7977 is a nucleotide prodrug associated with sofosbuvir and HCV NS5B polymerase inhibition. The cited BAP1 study describes SLC7A11, cystine, and NADPH in disulfidptosis, but it does not test PSI-7977 or establish a connection between the antiviral compound and BAP1 biology.

• Trypsin: Research Context, Uses, and Evidence

  2026-10-08

  Trypsin is a serine protease used across biochemical and cell biology research, but the strength of evidence varies substantially by application. This overview distinguishes supplier-described properties from peer-reviewed findings, examines conceptual uses in protein analysis, cell biology, wound healing research, neurogenic inflammation, and PDCoV membrane fusion, and explains why a rat osteoarthritis study on SMAD3, miRNA-140, and ADAMTS-5 does not establish a direct role for trypsin.

• C8-HSL in Quorum Sensing and Lung Cancer

  2026-10-07

  N-octanoyl-L-Homoserine lactone, or C8-HSL, is a bacterial quorum-sensing molecule studied in microbial communication and host–microbe biology. A 2026 FASEB Journal study reported that C8-HSL enhanced proliferation, migration, and invasion of H460 lung cancer cells and associated these effects with PI3K/AKT/ERK signaling. The findings are mechanistically suggestive but remain preliminary, with important limits concerning exposure relevance, model diversity, bacterial source attribution, and clinical applicability.

• Sex Differences in Angiotensin II Hypertension

  2026-10-07

  Xue, Pamidimukkala, and Hay showed that chronic angiotensin II exposure produces a substantially larger blood-pressure increase in conscious male mice than in females. Their telemetry, gonadectomy, baroreflex, and autonomic perturbation data connect this phenotype to sex-dependent hormonal and sympathetic mechanisms, while also defining important limits on mechanistic interpretation.

• Otilonium Bromide: Mapping Evidence Across Biology

  2026-10-06

  Otilonium Bromide is an antimuscarinic agent for studying cholinergic signaling and smooth muscle pharmacology. This article explains how to interpret its receptor-focused role alongside computational viral-enzyme research without confusing distinct targets, evidence levels, or biological applications.

• Tin Mesoporphyrin IX and HO-1 Translation

  2026-10-06

  Tin Mesoporphyrin IX (chloride) offers a mechanistic lens for testing how heme oxygenase activity intersects with oxidative signaling, viral biology, and metabolic disease research. This article interprets recent HBV findings while defining the evidence boundaries and translational questions that direct HO inhibition can help address.

• NSP15 Inhibitor Screening: Thymopentin and Oleuropein

  2026-10-05

  Vijayan and Gourinath used structure-based virtual screening and molecular dynamics simulations to identify thymopentin and oleuropein as promising predicted binders of SARS-CoV-2 NSP15. The study is valuable as a hypothesis-generating computational analysis, but its results do not establish biochemical inhibition, antiviral activity, or clinical efficacy.

• AM251 and CB1 Receptor Research: Evidence and Limits

  2026-10-05

  AM251 is a widely discussed CB1 receptor antagonist for mechanistic cannabinoid receptor research. This overview compares its reported pharmacology with findings from a 2026 mouse study of cannabidiol in inflammatory pain, emphasizing causal interpretation, evidence provenance, translational limits, and the distinction between supplier claims and primary research.

7998 records 3/534 page Previous Next 12345 下5页 Last page